ストックスクリーナーアプリを入手
1.7568
1.40%
-0.0332
前日終値:
$1.79
開ける：
$1.79
24時間の取引高:
11,128
Relative Volume:
0.01
時価総額：
$79.81M
収益：
-
当期純損益:
$-82.60M
株価収益率:
-0.8528
EPS:
-2.06
ネットキャッシュフロー:
$-48.61M
1週間 パフォーマンス:
+3.22%
1か月 パフォーマンス:
+0.86%
6か月 パフォーマンス:
-50.70%
1年 パフォーマンス:
-31.59%
1日の値動き範囲:
$1.75
$1.79
1週間の範囲:
$1.68
$1.87
52週間の値動き範囲:
$1.312
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
VIGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
1.76 | 79.81M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.43 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.34 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.72 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.53 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.25 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-04 | 開始されました | William Blair | Outperform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2022-09-16 | 開始されました | Wedbush | Outperform |
| 2022-08-29 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | 開始されました | Jefferies | Buy |
| 2022-02-01 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-01 | 開始されました | Stifel | Buy |
すべてを表示
Vigil Neuroscience Inc (VIGL) 最新ニュース
Vigil Neuroscience stock hits 52-week low at $1.43 - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $1.43 By Investing.com - Investing.com South Africa
Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com South Africa
Vigil presents data on oral small molecule program including VG-3927 - TipRanks
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com
Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan
Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks
Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World
Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India
FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World
Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World
HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks
Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com India
Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com
Vigil Neuroscience, Inc. SEC 10-K Report - TradingView
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq
Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq
Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire
Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan
SPY ETF News, 3/13/2025 - The Globe and Mail
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire
Vigil Neuroscience To Present At The Stifel 2025 Virtual CNS Forum - MENAFN.COM
Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance
Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire
What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat
abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Inc (VIGL) 財務データ
収益
当期純利益
現金流量
EPS
Vigil Neuroscience Inc (VIGL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
0.63%
大文字化:
|
ボリューム (24 時間):